Sugi Predict

Sugi Predict / Compounds / SCHEMBL10162264

SCHEMBL10162264

SCHEMBL10162264

CC(=O)C12CCC(CNC(=O)c3cc(C(=O)NCc4ccc(C(F)(F)F)cc4)nc4ncnn34)(CC1)CC2

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PDE2A O00408 4/20 0.39
▸ MBOAT4 Q96T53 1/20 0.38
▸ BRAF P15056 3/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ LSS P48449 1/20 0.35
▸ PSMD14 O00487 1/20 0.35
▸ STAMBP O95630 1/20 0.35
▸ HRH4 Q9H3N8 1/20 0.35
▸ RORC P51449 2/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MMP13 P45452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162257 0.91 HRH4 (0.46) BRAFCYP3A4HRH4MMP13
SCHEMBL10162262 0.91 SMN1; SMN2 (0.38) CYP3A4L3MBTL1MMP13
SCHEMBL10162263 0.89 MMP13 (0.45) PDE2AMBOAT4MMP13
SCHEMBL10162242 0.88 MMP13 (0.39) PDE2ACYP3A4MMP13
SCHEMBL10162199 0.88 PDE2A (0.40) PDE2ATRPV1CHRNB2CHRNB4CHRNA3
SCHEMBL10162240 0.86 MMP13 (0.48) PDE2ACYP3A4L3MBTL1MMP13
SCHEMBL10162252 0.85 MMP13 (0.40) PDE2AMMP13
SCHEMBL10162247 0.85 MMP13 (0.46) PDE2ABRAFTRPV1CHRNB2CHRNB4
SCHEMBL10162258 0.85 RIPK1 (0.39) PDE2AMBOAT4MMP13
SCHEMBL10162270 0.85 ALDH1A1 (0.33) CYP3A4L3MBTL1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885MBOAT4 2357/4885BRAF 3936/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 PDE2A 1534/4885MBOAT4 2357/4885BRAF 3936/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885MBOAT4 2357/4885BRAF 3936/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 PDE2A 1534/4885MBOAT4 2357/4885BRAF 3936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.